RxSight Q3 revenue falls on competitive pressures

What happened

RxSight's third-quarter revenue fell 19% compared with a year earlier, which the company said was mainly due to ongoing competitive pressures. Adjusted loss per share was $0.21, beating the $0.29 analyst estimate, and the company did not provide specific financial guidance.

Confirmed

Global impact / market context

A 19% revenue drop shows customers are choosing rival products, which pressures future sales. RxSight also faces higher inventory costs for its LAL and LDD products, which means it holds devices that cost more to make and may not sell, weighing on profit.

Analyst inference

Analysts rate the stock 'hold', with 1 buy, 7 hold, and 2 sell, and a median price target of $7.00 versus a $4.80 close, suggesting limited confidence in a quick recovery while rivals keep taking sales and no guidance is given.

Analyst inference

What to watch

1. RxSight reported minimal revenue from its Alcon collaboration because the program is in early stages, and it did not provide specific financial guidance for upcoming quarters or the full year. Confirmed
2. Watch whether competitive pressure eases, since a continued revenue decline would reduce cash from sales while inventory reserves and higher LAL and LDD inventory costs keep pressuring gross margin, which means profit per sale. Analyst inference
3. Track whether the expanded commercial leadership and completed restructuring translate into steadier sales, because analyst ratings and the $7.00 median target imply investors want evidence before repositioning. Analyst inference

Evidence

• Original source link unavailable